| True Health Vermont | |
|
217 Maxham Meadow Way, Woodstock, VT 05091-1162 | |
| (802) 332-6125 | |
| Not Available |
| Full Name | True Health Vermont |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 217 Maxham Meadow Way, Woodstock, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386260164 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Primary |
| Provider Name | Naomi N Malik |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1457407470 PECOS PAC ID: 6406866995 Enrollment ID: I20180307000540 |
News Archive
In the first ever study to assess the social impact of food allergies in children, Mount Sinai researchers have found that approximately 35 percent of children with food allergies, who are over the age of five, were reported to have experienced bullying, teasing, or harassment as a result of their allergies.
Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.
Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.
A new analysis finds that when colorectal cancer patients seek out health information from the internet and news media, they are more likely to be aware of and receive the latest treatments for their disease.
Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| True Health Vermont 5 Stanton St, Woodstock, VT 05091-1119 Ph: (401) 243-7288 | True Health Vermont 217 Maxham Meadow Way, Woodstock, VT 05091-1162 Ph: (802) 332-6125 |
News Archive
In the first ever study to assess the social impact of food allergies in children, Mount Sinai researchers have found that approximately 35 percent of children with food allergies, who are over the age of five, were reported to have experienced bullying, teasing, or harassment as a result of their allergies.
Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.
Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.
A new analysis finds that when colorectal cancer patients seek out health information from the internet and news media, they are more likely to be aware of and receive the latest treatments for their disease.
Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.
› Verified 8 days ago
Dr. Andrea Kristen Kannas, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 442 Woodstock Rd, Suite 5a, Woodstock, VT 05091 Phone: 802-332-6125 Fax: 802-332-8015 | |
Dr. Steven C. Drebber, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 32 Pleasant St, Woodstock, VT 05091 Phone: 802-457-3355 Fax: 802-457-3062 | |
Dr. Joshua Taylor Gale, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 39 Central St, Suite 201a, Woodstock, VT 05091 Phone: 802-291-2288 | |
Chiropractic & Wellness Studio Pllc Chiropractor Medicare: Medicare Enrolled Practice Location: 442 Woodstock Rd, Suite 5a, Woodstock, VT 05091 Phone: 802-332-6125 Fax: 802-332-8015 |